Oncotarget: Rapid onset type 1 diabetes with anti-PD-1 directed therapy

(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features 'Rapid onset type 1 diabetes with anti-PD-1 directed therapy', by Yun et al. and reported that Type 1 diabetes is a rare immune-related adverse event caused by checkpoint inhibitors with serious risk for diabetic ketoacidosis.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

WEDNESDAY, Oct. 7, 2020 -- After starting a drug that's officially approved to treat a type of blood cancer, a young man with type 1 diabetes was able to stop using insulin. He's been off insulin since August 2018 -- more than two years. Dr. Lisa...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Nivolumab, a fully human IgG4 immune checkpoint inhibitor (ICI) antibody, has been approved for a variety of cancers. Several endocrine-associated immune-related adverse events have been reported, but the incidence rate is relatively low. This is a case of a patient with gastric cancer who underwent nivolumab therapy, leading to type 1 diabetes as well as adrenocorticotropic hormone (ACTH) deficiency and hypothyroidism almost simultaneously. A 70-year-old man with no previous history of diabetes was treated with nivolumab monotherapy for gastric cancer in November 2018. After 8 courses of nivolumab, he was diagnosed with t...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, it remains unclear if brain-specific regional and temporal changes occur in the expression of the different APP variants during AD progression. Since APP is also found in blood cells, assessing the changes in APP mRNA expression in peripheral blood cells from AD patients has been considering an alternative. However, again the quantification of APP mRNA in peripheral blood cells has generated controversial results. Brain APP protein has been analyzed in only a few studies, probably as it is difficult to interpret the complex pattern of APP variants and fragments. We previously characterized the soluabl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
I recently collaborated on a review paper covering the history of clinical work on upregulation of nicotinamide adenine dinucleotide (NAD) as an approach to therapy. This is of interest to the aging research community because NAD is important to mitochondrial function. NAD levels diminish with age, alongside a loss of mitochondrial function that is known to contribute to the onset and progression of many age-related conditions. Animal studies and a few clinical trials have indicated that increased NAD levels may improve, for example, cardiovascular function in older individuals, as a result of improved mitochondrial functi...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
This article will provide essential considerations concerning the physicochemical properties of the most commonly used biomaterials, relevant aspects of the immune response to bioencapsulation, current encapsulation strategies, potential implantation sites for encapsulated cell therapies and, finally, a comprehensive review on the current state of clinical translation. © 2020 American Physiological Society. Compr Physiol 10:839-878, 2020. PMID: 32941683 [PubMed - in process]
Source: Comprehensive Physiology - Category: Physiology Tags: Compr Physiol Source Type: research
AbstractRecentHealthy Drinks, Healthy Kids (HDHK) guidelines state children between 12 and 24  months need to be consuming 2–3 cups a day of whole fat cow’s milk, and less of all other beverages except water. Guidelines explicitly state plant-based milks should be avoided (with the exception of soy milk). We agree that in the first 12 months the optimal food for childhood growth is bre ast milk, with formula used where needed. However, after weaning, milk of any kind is not required, and should not be relied upon as a main source of calories. Children will be fine with water and a healthy balanced die...
Source: Maternal and Child Health Journal - Category: Health Management Source Type: research
Abstract Vaccines are well-known therapies for infectious disease and cancer; however, recently, we and others have developed vaccines for other chronic diseases, such as hypertension, diabetes and dyslipidemia. Although we have many treatment options for hypertension, including angiotensin II type 1 receptor blockers, calcium-channel blockers, and diuretics, a substantial portion of the hypertensive population has uncontrolled blood pressure due to poor medication adherence. When these vaccines are established in the future as therapeutic options for chronic diseases, their administration regimen, such as several...
Source: Circulation Journal - Category: Cardiology Authors: Tags: Circ J Source Type: research
The spectrum of endocrine side-effects during immune checkpoint inhibition (ICI) comprises not only frequent toxicities such as thyroid function disorders and hypophysitis but also rare events such as immune checkpoint inhibitor –induced type 1 diabetes mellitus (CPI-T1DM). CPI-T1DM is defined as a severe insulin deficiency and clinically characterised by the situation of ketoacidosis and low levels of or absence of C-peptide [1]. In the pivotal trial (Keynote-054) for the adjuvant treatment of melanoma, a flat dose of 20 0 mg of pembrolizumab (PEM) was applied every 3 weeks.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
Basel, 1 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas ® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.“Roche is committed to improving diagnostic technologies in the fight against HIV/AIDS,” said Thomas Schinecker, CEO Roche Diagnostics. “Being able to reliably determi...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
In conclusions, ICI-induced type 1 diabetes is a potentially life-threating adverse event after the immunotherapy of cancers. Screening and early recognition is important. Further investigation of the mechanism may help to better understand the pathology of type 1 diabetes. PMID: 32842016 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Type 1 | Endocrinology